Advancing The Role Of The Sglt2 Inhibitors In The T2d Treatment Paradigm | Latest News RSS feed WordPress.com

Advancing The Role Of The Sglt2 Inhibitors In The T2d Treatment Paradigm - Latest News


How The Global Pharma Industry Will Shape Up In The Next 5 Years?

The 39 novel drugs approved in FY 2012 includes groundbreaking treatment for a form of cystic fibrosis, the first human cord blood product ever approved, and the first drugs to treat advanced basal .. ... read more

New England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes

today announced that the New England Journal of Medicine (NEJM) published the results of the Phase 3 inTandem3 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for the treatm... read more

Poxel Announces Completion of Patient Enrollment for TIMES 1 Tri - WSFA.com Montgomery Alabama news.

In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor ... organs which play an im... read more

Looking for another news?


Poxel Announces Completion of Patient Enrollment for TIMES 1 Tri - wistv.com - Columbia, South Carolina

In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor ... organs which play an im... read more


Poxel Announces Completion of Patient Enrollment for TIMES 1 Tri - Honolulu, Hawaii news, sports & weather - KITV Channel 4

In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor ... organs which play an im... read more

Poxel Announces Completion of Patient Enrollment for TIMES 1 Tri - KSWO 7News | Breaking News, Weather and Sports

In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor ... organs which play an im... read more

Poxel Announces Completion of Patient Enrollment for TIMES 1 Tri - ABC6 - Providence, RI and New Bedford, MA News, Weather

In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor ... organs which play an im... read more

Merck and : - Late-Breaking Data to be presented from the Comparative Trials with Sitagliptin Program on the Continuation of JANUVIA Treatment

Presentations include efficacy and safety data for JANUVIA in various settings across the treatment paradigm. Data on the long-term ... in patients with type 1 and type 2 diabetes receiving SGLT2 inhi... read more

Poxel Provides Business Update and Reports Results for Full Year 2017

In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor ... Phase 1 and 2 programs. ... read more

AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes

1 ” Further exploratory analysis of BYDUREON and glucose fluctuations was provided in the poster “Effects of Exenatide Once Weekly on Dynamics of 24h Glucose Patterns in Patients with T2D ... treatmen... read more

Lexicon Pharmaceuticals' CEO Discusses LX4211 Positive Results in Type 1 Diabetes Clinical Trial (Transcript)

We admitted into the study both the two major forms of insulin treatment currently for type 1 diabetes which ... which contrast was what has been seen with some of the SGLT2 selective compounds in sim... read more

New England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes

The combination of these effects provides a differentiated drug profile and the opportunity for sotagliflozin to transform the treatment paradigm ... SGLT1 and SGLT2 inhibitor mechanism of action in d... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us